Recently, tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated considerable efficacy in improving glycemic control and promoting weight reduction in patients with obesity (7–9). Here, GIP is linked to obesity disorder.